Efficacy of α-lipoic acid in diabetic neuropathy

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 18, 2014, Pages 2721-2731

  Papanas, Nikolaos ^a   Ziegler, Dan ^b,c  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Diabetes mellitus; Diabetic neuropathy; Efficacy; Oxidative stress; Thioctic acid; Treatment

Indexed keywords

THIOCTIC ACID; ANTIOXIDANT; REACTIVE OXYGEN METABOLITE;

ABDOMINAL DISCOMFORT; ANXIETY; BLOOD FLOW; CLINICAL PRACTICE; CORPUS CAVERNOSUM; DERMATITIS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HUMAN; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; LARYNX SPASM; META ANALYSIS (TOPIC); MUSCLE STRENGTH; NAUSEA AND VOMITING; NERVE; NERVE BLOOD FLOW; NERVE CONDUCTION; NERVE FUNCTION; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PARESTHESIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP DISORDER; URTICARIA; VERTIGO; CHEMISTRY; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC NEUROPATHIES; HALF LIFE TIME; METABOLISM; PATHOLOGY;

ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC NEUROPATHIES; HALF-LIFE; HUMANS; REACTIVE OXYGEN SPECIES; THIOCTIC ACID;

EID: 84910627065     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.972935     Document Type: Review

References (90)

1. Ziegler D, Rathmann W, Dickhaus T, KORA Study Group. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008;31: 464-9
2. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33: 2285-93
3. Papanas N, Maltezos E. The diabetic foot: established and emerging treatments. Acta Clin Belg 2007;62: 230-8
4. Resnick HE, Vinik AI, Schwartz AV, et al. Independent effects of peripheral nerve dysfunction on lower-extremity physical function in old age. The Women's Health and Aging Study. Diabetes Care 2000;23: 1642-7
5. Vaaaaarkonyi T, Putz Z, Keresztes K, et al. Current options and perspectives in the treatment of diabetic neuropathy. Curr Pharm Des 2013;19: 4981-5007
6. Galer BS, Gianas A, Jensen MP. Painful diabetic neuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000;47: 123-8
7. Forsblom CM, Sane T, Groop PH, et al. Risk factors for mortality in Type II (non-insulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4. Diabetologia 1998;4: 1253-62
8. Coppini DV, Bowtell PA, Weng C, et al. Showing neuropathy is related to increased mortality in diabetic patients-A survival analysis using an accelerated failure time model. J Clin Epidemiol 2000;53: 519-23
9. Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 2011;27: 639-53
10. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007;115: 387-97
11. Vinik AI, Maser RE, Ziegler D. Neuropathy: the crystal ball for cardiovascular disease? Diabetes Care 2010;33: 1688-90
12. Papanas N, Ziegler D. New vistas in the diagnosis of diabetic polyneuropathy. Endocrine 2014. [Epub ahead of print]
13. Papanas N, Boulton AJ, Malik RA, et al. A simple new non-invasive sweat indicator test for the diagnosis of diabetic neuropathy. Diabet Med 2013;30: 525-34
14. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985;8: 491-8
15. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 2012;6: CD007543
16. Papanas N, Maltezos E. Alpha-lipoic acid, diabetic neuropathy, and Nathan's prophecy. Angiology 2012;63: 81-3
17. Boulton AJ, Kempler P, Ametov A, Ziegler D. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes Metab Res Rev 2013;29: 327-33
18. Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat Endocrinol 2004;3: 173-89
19. Tiaka EK, Papanas N, Manolakis AC, Maltezos E. The role of nerve growth factor in the prophylaxis and treatment of diabetic foot ulcers. Int J Burns Trauma 2011;1: 68-76
20. Bril V, Hirose T, Tomioka S, Buchanan R; Ranirestat Study Group. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 2009;32: 1256-60
21. Schemmel KE, Padiyara RS, D'Souza JJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. J Diabetes Complications 2010;24: 354-60
22. Bansal D, Badhan Y, Gudala K, Schifano F. Ruboxistaurin for the treatment of diabetic peripheral neuropathy: a systematic review of randomized clinical trials. Diabetes Metab J 2013;37: 375-84
23. Davis TM, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 2008;51: 562-6
24. Antonoglou C, Papanas N, Maltezos E. Lipid-lowering therapy in the diabetic foot: seeing the whole iceberg and not just the tip. Curr Vasc Pharmacol 2012. [Epub ahead of print]
25. Rajamani K, Colman PG, Li LP, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009;373: 1780-8
26. Vincent AM, Hayes JM, McLean LL, et al. Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes 2009;58: 2376-85
27. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005;352: 341-50
28. Papanas N, Vinik AI, Ziegler D. Neuropathy in prediabetes: does the clock start ticking early? Nat Rev Endocrinol 2011;7: 682-90
29. Available from: http://pubchem.ncbi.nlm. nih.gov/summary/summary.cgi?cid=6112 [Last accessed 5 July 2014]
30. Available from: http://toxnet.nlm.nih. gov/cgi-bin/sis/search2/r?dbs+hsdb: @term +@rn+@rel+1077-28-7 [Last accessed 5 July 2014]
31. Carlson DA, Smith AR, Fischer SJ, et al. The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects. Altern Med Rev 2007;12: 343-51
32. Haak ES, Usadel KH, Kohleisen M, et al. The effect of alpha-lipoic acid on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy. Microvasc Res 1999;58: 28-34
33. Haak E, Usadel KH, Kusterer K, et al. Effects of alpha-lipoic acid on microcirculation in patients with peripheral diabetic neuropathy. Exp Clin Endocrinol Diabetes 2000;108: 168-74
34. Heitzer T, Finckh B, Albers S, et al. Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med 2001;31: 53-61
35. Hoffman M, Zimmer G. Lipoate prevention of diabetic microangiopathy. In: Fuchs J, Packer L, Zimmer G, editors. Lipoic acid in health and disease. Marcel Decker; New York: 1997. p. 168-74
36. Sola S, Mir MQ, Cheema FA, et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the irbesartan and lipoic acid in endothelial dysfunction (ISLAND) study. Circulation 2005;111: 343-8
37. Borcea V, Nourooz-Zadeh J, Wolff SP, et al. Alpha-Lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Free Radic Biol Med 1999;26: 1495-500
38. Androne L, Gavan NA, Veresiu IA, Orasan R. In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. In Vivo 2000;14: 327-30
39. Hofmann MA, Schiekofer S, Kanitz M, et al. Insufficient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care 1998;21: 1310-16
40. Hofmann MA, Schiekofer S, Isermann B, et al. Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-kappaB. Diabetologia 1999;42: 222-32
41. Jacob S, Henriksen EJ, Tritschler HJ, et al. Improvement of insulin-stimulated glucose-disposal in type 2 diabetes after repeated parenteral administration of thioctic acid. Exp Clin Endocrinol Diabetes 1996;104: 284-8
42. Jacob S, Rett K, Henriksen EJ, Haddddring HU. Thioctic acid-effects on insulin sensitivity and glucose-metabolism. Biofactors 1999;10: 169-74
43. Evans JL, Goldfine ID. Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. Diabetes Technol Ther 2000;2: 401-13
44. Barbiroli B, Medori R, Tritschler HJ, Iotti S. Thioctic acid stimulates muscle ATP production in patients with type-2-diabetes and diabetic polyneuropathy. Diabetes Stoffwechsel 1996;5(3 Suppl): 71-6
45. Nagamatsu M, Nickander KK, Schmelzer JD, et al. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995;18: 1160-7
46. Nickander KK, McPhee BR, Low PA, Tritschler H. Alpha-lipoic acid: antioxidant potency against lipid peroxidation of neural tissues in vitro and implications for diabetic neuropathy. Free Radic Biol Med 1996;21: 631-9
47. Stevens MJ, Obrosova I, Cao X, et al. Effects of DL-Alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 2000;49: 1006-15
48. Garrett NE, Malcangio M, Dewhurst M, Tomlinson DR. Alpha-Lipoic acid corrects neuropeptide deficits in diabetic rats via induction of trophic support. Neurosci Lett 1997;222: 191-4
49. Bierhaus A, Chevion S, Chevion M, et al. Advanced glycation end productinduced activation of NF-kB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 1997;46: 1481-90
50. Mitsui Y, Schmelzer JD, Zollman PJ, et al. Alpha-lipoic acid provides neuroprotection from ischemiareperfusion injury of peripheral nerve. J Neurol Sci 1999;163: 11-16
51. Coppey LJ, Gellett JS, Davidson EP, et al. Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 2001;50: 1927-37
52. Cameron NE, Jack AM, Cotter MA. Effect of alpha-lipoic acid on vascular responses and nociception in diabetic rats. Free Radic Biol Med 2001;31: 125-35
53. Gomes MB, Negrato CA. Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. Diabetol Metab Syndr 2014;6: 80
54. Santos JM, Kowluru RA. Role of mitochondria biogenesis in the metabolic memory associated with the continued progression of diabetic retinopathy and its regulation by lipoic acid. Invest Ophthalmol Vis Sci 2011;52: 8791-8
55. Roberts R, Luan H, Berkowitz BA. Alpha-lipoic acid corrects late-phase supernormal retinal oxygenation response in experimental diabetic retinopathy. Invest Ophthalmol Vis Sci 2006;47: 4077-82
56. Berkowitz BA, Roberts R, Stemmler A, et al. Impaired apparent ion demand in experimental diabeticretinopathy: correction by lipoic Acid. Invest Ophthalmol Vis Sci 2007;48: 4753-8
57. Haritoglou C, Gerss J, Hammes HP, RETIPON Study Group. Alpha-lipoic acid for the prevention of diabetic macular edema. Ophthalmologica 2011;226: 127-37
58. Nebbioso M, Federici M, Rusciano D, et al. Oxidative stress in preretinopathic diabetes subjects and antioxidants. Diabetes Technol Ther 2012;14: 257-63
59. Yi X, Xu L, Hiller S, et al. Reduced expression of lipoic acid synthase accelerates diabetic nephropathy. J Am Soc Nephrol 2012;23: 103-11
60. Bhatti F, Mankhey RW, Asico L, et al. Mechanisms of antioxidant and prooxidant effects of alpha-lipoic acid in the diabetic and nondiabetic kidney. Kidney Int 2005;67: 1371-80
61. Wang L, Wu CG, Fang CQ, et al. The protective effect of alpha-Lipoic acid on mitochondria in the kidney of diabetic rats. Int J Clin Exp Med 2013;6: 90-7
62. Chang JW, Lee EK, Kim TH, et al. Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study. Am J Nephrol 2007;27: 70-4
63. Morcos M, Borcea V, Isermann B, et al. Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res Clin Pract 2001;52: 175-83
64. Noori N, Tabibi H, Hosseinpanah F, et al. Effects of combined lipoic acid and pyridoxine on albuminuria, advanced glycation end-products, and blood pressure in diabetic nephropathy. Int J Vitam Nutr Res 2013;83: 77-85
65. Keegan A, Cotter MA, Cameron NE. Corpus cavernosum dysfunction in diabetic rats: effects of combined alphalipoic acid and gamma-linolenic acid treatment. Diabetes Metab Res Rev 2001;17: 380-6
66. Hurdag C, Ozkara H, Citci S, et al. The effects of alpha-lipoic acid on nitric oxide synthetase dispersion in penile function in streptozotocin-induced diabetic rats. Int J Tissue React 2005;27: 145-50
67. Mitkov MD, Aleksandrova IY, Orbetzova MM. Effect of transdermal testosterone or alpha-lipoic acid on erectile dysfunction and quality of life in patients with type 2 diabetes mellitus. Folia Med (Plovdiv) 2013;55: 55-63
68. Teichert J, Hermann R, Ruus P, Preiss R. Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers. J Clin Pharmacol 2003;43: 1257-67
69. Teichert J, Tuemmers T, Achenbach H, et al. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease. J Clin Pharmacol 2005;45: 313-28
70. Reljanovic M, Reichel C, Rett K, et al. Treatment of diabetic peripheral neuropathy with the antioxidant thioctic acid (alpha-lipoic acid). A two-year multicenter randomized double blind placebo controlled trial (ALADIN II). Free Rad Res 1999;31: 171-9
71. Ruhnau K-J, Meissner HP, Finn JR, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alphalipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med 1999;16: 1040-3
72. Ziegler D, Schatz H, Conrad F, et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Diabetes Care 1997;20: 369-73
73. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: The SYDNEY 2 trial. Diabetes Care 2006;29: 2365-70
74. Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011;34: 2054-60
75. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995;38: 1425-33
76. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid. A 7-month multicenter randomized controlled trial (ALADIN III Study). Diabetes Care 1999;22: 1296-301
77. Ametov A, Barinov A, O'Brien P, et al. The sensory symptoms of diabetic polyneuropathy are improved with alphalipoic acid. The SYDNEY Trial. Diabetes Care 2003;26: 770-6
78. Rathmann W, Haastert B, Delling B, et al. Postmarketing surveillance of adverse drug reactions: a correlational study approach usingmultiple data sources. Pharmacoepidemiol Drug Saf 1998;7: 51-7
79. Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-Analysis. Diabet Med 2004;21: 114-21
80. McIlduff CE, Rutkove SB. Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Ther Clin Risk Manag 2011;7: 377-85
81. Mijnhout GS, Kollen BJ, Alkhalaf A, et al. Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-Analysis of randomized controlled trials. Int J Endocrinol 2012;2012: 456279
82. Han T, Bai J, Liu W, Hu Y. A systematic review and meta-Analysis of alpha-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol 2012;167: 465-71
83. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev 2014;1: CD007115
84. Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab Res Rev 2008;24(Suppl 1): S52-7
85. Ruessmann HJ; German Society of out patient diabetes centres AND (Arbeitsgemeinschaft niedergelassener diabetologisch taddddtiger Arzte e.V.). Switching from pathogenetic treatment with alpha-lipoic acid to gabapentin and other analgesics in painful diabetic neuropathy: a real-world study in outpatients. J Diabetes Complications 2009;23: 174-7
86. Snedecor SJ, Sudharshan L, Cappelleri JC, et al. Systematic review and meta-Analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract 2014;14: 167-84
87. Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011;76: 1758-65
88. Peltier A, Goutman SA, Callaghan BC. Painful diabetic neuropathy. BMJ 2014;348: g1799
89. Kalso E, Aldington DJ, Moore RA. Drugs for neuropathic pain. BMJ 2013;347: f7339
90. Fonseca VA, Lavery LA, Thethi TK, et al. Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial. Am J Med 2013;126: 141-9